INFORMATION FOR ADULT PATIENTS PRESCRIBED XGEVA (DENOSUMAB) in the United Kingdom

This site is designed by Amgen for adult patients who have been prescribed XGEVA^® (denosumab). XGEVA^® is a single subcutaneous injection given in the thigh, abdomen or upper arm every four weeks. XGEVA^® is made from a protein called denosumab, which works by slowing down the breakdown of bone. This treatment is used in adults with cancer to prevent skeletal-related events, caused by bone metastases.

XGEVA is available as a Pre-filled Syringe and as a Vial Preparation. Only the Pre-filled syringe allows self-administration after appropriate training.

Should you have any concerns or questions regarding your treatment please speak to your doctor/nurse.

For more information on your treatment (eg possible side effects, what you need to know before using XGEVA, including warnings and precautions, how to store XGEVA and instructions for use) please refer to the patient information leaflet

Reporting of Side Effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. Side effects can also be reported to Amgen Ltd on 01223 436441.

XGEVA : Prevention of skeletal related events in adults with advanced malignancies involving bone

This guide is for adult patients prescribed XGEVA and has been created to provide information about your treatment.
Click the button below to download a PDF version of the booklet

A booklet for patients prescribed XGEVA (denosumab)

Download Pdf

Self-administration with XGEVA Pre-filled syringe

XGEVA pre-filled syringe can be self administered by the patient or carer, after being trained in injection techniques by a healthcare professional. Your healthcare professional may give you or your carer the option to self-administer your pre-filled syringe at home , but the first self-administration of the pre-filled syringe should be supervised by a healthcare professional.

Please see below two materials which have been created to provide step-by-step instructions on the administration of XGEVA.

Please note: unless you or your caregiver has received training by a healthcare professional, do not try to give yourself the injection.

A self-administration booklet for patients prescribed XGEVA pre-filled syringe

Download Pdf

DOWNLOAD TRANSCRIPT (ENGLISH)

These materials have been developed by Amgen to support with self-administration of XGEVA at home. They are intended to supplement, but not replace, the guidance of your prescribing health care provider, who should be contacted if you have any questions with regard to denosumab or self administration.

Patient Information Leaflets:

Patient reminder cards:

This reminder card contains important safety information that patients need to be aware of before and during treatment with denosumab (XGEVA) injections for cancer-related conditions, A side effect called osteonecrosis of the jaw (ONJ, bone damage in the jaw) has been reported commonly (may affect up to 1 in 10 people) in patients receiving XGEVA injections for cancer-related conditions